Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021
Maria Abbattista, Alessandro Ciavarella, Declan Noone, Flora Peyvandi
Topics & Concepts
MedicineAdverse effectInternal medicineOdds ratioAdverse drug reactionDrugGastroenterologyPharmacologyHemophilia Treatment and ResearchCoagulation, Bradykinin, Polyphosphates, and AngioedemaHeparin-Induced Thrombocytopenia and Thrombosis